MAO is a flavin-containing enzyme critical for regulating MAO inhibitors and other serotonergic drugs is associated with the
Newer MAO inhibitor drugs, including selegiline (Eldepryl) and rasagiline (Azilect), target MAO-B and are called selective MAO inhibitors. Selegiline is
The efficacy of the inhibitor binding into the unique substrate binding sites of MAO-A and MAO-B ultimately determines a drug s relative selectivity at inhibiting MAO-A, MAO-B, or both. The substrate binding sites of both MAO-A and MAO-B are mainly hydrophobic except for a conserved lysine that interacts with a water molecule.
The monoamine oxidase (MAO) enzymes include MAO-A and MAO-B. The catecholamines are metabolized by both MAO-A and MAO-B, whereas 5-HT is metabolized only by MAO-A. The four irreversible MAOIs marketed in the United States include the nonselective MAOIs phenelzine and tranylcypromine and the MAO-B selective drugs selegiline and isocarboxazid ((2)).
The efficacy of the inhibitor binding into the unique substrate binding sites of MAO-A and MAO-B ultimately determines a drug s relative selectivity at inhibiting MAO-A, MAO-B, or both. The substrate binding sites of both MAO-A and MAO-B are mainly hydrophobic except for a conserved lysine that interacts with a water molecule.
The efficacy of the inhibitor binding into the unique substrate binding sites of MAO-A and MAO-B ultimately determines a drug s relative selectivity at inhibiting MAO-A, MAO-B, or both. The substrate binding sites of both MAO-A and MAO-B are mainly hydrophobic except for a conserved lysine that interacts with a water molecule.
Drug Administration in the United States on . List of MAO inhibiting drugs. edit. Marketed MAOIs. edit. Nonselective MAO-A/MAO-B inhibitors.
A drug that prevents the activity of the enzyme monoamine oxidase (MAO). MAO inhibitors include phenelzine, isocarboxazid, and tranylcypromine. These drugs
Examples of Drugs 1.Non-selective MAO inhibitors Inhibit both MAO-A. Examples of Drugs 2.Selective MAO-A Inhibitor Clorgiline (Clorgyline) .
Comments